Page 23 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Progress in the research of pathology and therapy in liver fibrosis

fatty liver disease in lean individuals: Expert review. 63. Krassenburg LA, Maan R, Ramji A, et al. Clinical outcomes
Gastroenterology. 2022;163(3):764-774.e1. following DAA therapy in patients with HCV-related cirrhosis
depend on disease severity. J Hepatol. 2021;74(5):1053-1063.
doi: 10.1053/j.gastro.2022.06.023
53. Keegan A, Malamal G, Lee Y, et al. Multi-modal diagnostic doi: 10.1016/j.jhep.2020.11.021
imaging of metabolic dysfunction-associated steatotic liver 64. Koutoukidis DA, Astbury NM, Tudor KE, et al. Association
disease: Non-invasive analyses by photoacoustic ultrasound of weight loss interventions with changes in biomarkers of
and MRI. Am J Pathol. 2025. nonalcoholic fatty liver disease: A systematic review and
doi: 10.1016/j.ajpath.2025.01.012 meta-analysis. JAMA Intern Med. 2019;179(9):1262-1271.
54. Gao J, Wang Y, Meng X, et al. A FAPalpha-activated MRI doi: 10.1001/jamainternmed.2019.2248
nanoprobe for precise grading diagnosis of clinical liver 65. Huang DQ, El-Serag HB, Loomba R. Global epidemiology
fibrosis. Nat Commun. 2024;15(1):8036. of NAFLD-related HCC: trends, predictions, risk factors and
doi: 10.1038/s41467-024-52308-3 prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223-238.
55. Duarte-Rojo A, Taouli B, Leung DH, et al. Imaging-based doi: 10.1038/s41575-020-00381-6
noninvasive liver disease assessment for staging liver fibrosis 66. Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global
in chronic liver disease: A systematic review supporting the epidemiology of alcohol-associated cirrhosis and HCC:
AASLD Practice Guideline. Hepatology. 2025;81(2):725-748. Trends, projections and risk factors. Nat Rev Gastroenterol
doi: 10.1097/HEP.0000000000000852 Hepatol. 2023;20(1):37-49.
56. Liver EAftSot. EASL 2017 Clinical Practice Guidelines on doi: 10.1038/s41575-022-00688-6
the management of hepatitis B virus infection. J Hepatol. 67. Blanc JF, Khemissa F, Bronowicki JP, et al. Phase 2 trial
2017;67(2):370-398. comparing sorafenib, pravastatin, their combination or
doi: 10.1016/j.jhep.2017.03.021 supportive care in HCC with Child-Pugh B cirrhosis.
Hepatol Int. 2021;15(1):93-104.
57. Yuen MF, Ahn SH, Chen DS, et al. Chronic Hepatitis B
virus infection: Disease revisit and management doi: 10.1007/s12072-020-10120-3
recommendations. J Clin Gastroenterol. 2016;50(4):286-294. 68. Hao H, Zhang D, Shi J, et al. Sorafenib induces autophagic
doi: 10.1097/MCG.0000000000000478 cell death and apoptosis in hepatic stellate cell through
the JNK and Akt signaling pathways. Anticancer Drugs.
58. Li Q, Sun B, Zhuo Y, et al. Interferon and interferon- 2016;27(3):192-203.
stimulated genes in HBV treatment. Front Immunol.
2022;13:1034968. doi: 10.1097/CAD.0000000000000316
doi: 10.3389/fimmu.2022.1034968 69. Su TH, Shiau CW, Jao P, et al. Sorafenib and its derivative
SC-1 exhibit antifibrotic effects through signal transducer
59. Maan R, van Tilborg M, Deterding K, et al. Safety and activator of transcription 3 inhibition. Proc Natl Acad
and effectiveness of direct-acting antiviral agents for Sci U S A. 2015;112(23):7243-7248.
treatment of patients with chronic hepatitis C virus
infection and cirrhosis. Clin Gastroenterol Hepatol. doi: 10.1073/pnas.1507499112
2016;14(12):1821-1830.e6. 70. Yuan S, Wei C, Liu G, et al. Sorafenib attenuates liver fibrosis
doi: 10.1016/j.cgh.2016.07.001 by triggering hepatic stellate cell ferroptosis via HIF-1α/
SLC7A11 pathway. Cell Prolif. 2022;55(1):e13158.
60. Verna EC, Morelli G, Terrault NA, et al. DAA therapy and
long-term hepatic function in advanced/decompensated doi: 10.1111/cpr.13158
cirrhosis: Real-world experience from HCV-TARGET 71. Chen XF, Ji S. Sorafenib attenuates fibrotic hepatic injury
cohort. J Hepatol. 2020;73(3):540-548. through mediating lysine crotonylation. Drug Des Devel
doi: 10.1016/j.jhep.2020.03.031 Ther. 2022;16:2133-2144.
61. Oltmanns C, Liu Z, Mischke J, et al. Reverse inflammaging: doi: 10.2147/DDDT.S368306
Long-term effects of HCV cure on biological age. J Hepatol. 72. Wang E, Liao Z, Wang L, et al. A combination of pirfenidone
2023;78(1):90-98. and TGF-β inhibition mitigates cystic echinococcosis-
doi: 10.1016/j.jhep.2022.08.042 associated hepatic injury. Parasitology. 2021;148(7):767-778.
62. Liver EAftSot. EASL recommendations on treatment doi: 10.1017/S0031182021000287
of hepatitis C: Final update of the series. J Hepatol. 73. Komiya C, Tanaka M, Tsuchiya K, et al. Antifibrotic effect
2020;73(5):1170-1218.
of pirfenidone in a mouse model of human nonalcoholic
doi: 10.1016/j.jhep.2020.08.018 steatohepatitis. Sci Rep. 2017;7:44754.

Volume 9 Issue 3 (2025) 15 doi: 10.36922/ejmo.8125